Hepatitis News : Hep C Patients Receiving Optimum Care Have Better Cure Rates

A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis News » November 2012


November 12, 2012

Hep C Patients Receiving Optimum Care Have Better Cure Rates

Those who receive optimum hepatitis C virus (HCV) care are much more likely to undergo antiviral treatment, complete their treatment and achieve a sustained virological response (SVR), according to a new study published in the journal Clinical Gastroenterology and Hepatology. The most significant factor associated with increased treatment and cure rates was the care offered by providers before treatment for hep C.

A consortium of researchers analyzed data from almost 35,000 hepatitis C patients, drawn from the 2003 to 2006 records of the Veterans Administration HCV Clinical Case Registry. The scientists compared the relationship of optimum versus sub-optimum care in three categories—pretreatment care, preventative or comorbidity care, and treatment monitoring—to three separate end points: antiviral treatment, completion of treatment, and SVR.

Compared with patients who received sub-optimum care, those who received optimum pre-treatment care were more than three times more likely to undergo antiviral treatment, 25 percent more likely to complete treatment, and 29 percent more likely to experience an SVR. Optimum preventative or comorbidity care was associated with a 36 percent increase in antiviral treatment rates. The study’s authors stressed that health care providers should use these findings to help guide clinical practice.

To read a copy of the study abstract, click here.

Search: Hepatitis C, HCV, virus, optimum treatment, sustained virological response, SVR, Clinical Gastroenterology and Hepatology, Veterans Administration HCV Clinical Case Registry, pretreatment care, preventative, comorbidity, treatment monitoring, antiviral treatment.

Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
Current Issue
Hep TV
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Do you think Gilead should lower the price for its new hepatitis C drug, Sovaldi?
Not sure

USA Today/Hepatitis C Awareness Survey

Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.